Back to Authors

Wonderlich, Stephen A.

https://orcid.org/0000-0002-0659-153X

Mayo Clinic

University of North Dakota

Citations 1

Adapting integrative cognitive‐affective therapy for adolescents with full and subthreshold bulimia nervosa: A feasibility study
Lebow, Jocelyn , Sim, Leslie , Wonderlich, Stephen A. , Peterson, Carol B. , Lebow, Jocelyn

European Eating Disorders Review | August 15, 2022 | Volume: 31 | Issue: 1 | Pages: 178-187

10.1002/erv.2946 Get It

AbstractBackgroundIntegrative Cognitive Affective Therapy (ICAT) is an empirically supported treatment for bulimia nervosa (BN) in adults. However, it is unclear whether a modified version, Integrative Cognitive Affective Therapy–Adolescent (ICAT‐A) is feasible and beneficial for adolescents. This study evaluated the feasibility of ICAT‐A for adolescents with BN or subthreshold BN.MethodsEight adolescents with BN or subthreshold BN (mean age = 16.1) were enroled in the study. At baseline and end of treatment, adolescents who participated in ICAT‐A completed the Eating Disorder Examination (EDE) and self‐report measures of eating disorder symptoms, depression, anxiety, self‐esteem and functional impairment.ResultsRetention for the intervention (75%) suggests that the majority of participants found the intervention acceptable. Although all treatment completers participated in the clinician‐administered assessment (EDE), compliance with end of treatment self‐report questionnaires was compromised by the COVID‐19 pandemic, which occurred during the treatment course of the majority of the sample. At the end of treatment, all 6 adolescents who completed the ICAT‐A intervention were in full eating disorder remission based on EDE scores, with large effect sizes identified for reductions in EDE global scores (d = 2.71), objective binge episodes (d = 0.91), subjective binge episodes (d = 1.06) and compensatory behaviours (d = 1.72).ConclusionResults suggest that ICAT‐A is a feasible treatment that has promise for the treatment of adolescents with BN. Future studies are necessary to establish the efficacy of ICAT‐A for adolescent BN.